ClinicalTrials.gg
RecruitingNCT06623578Updated Dec 3, 2025

Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC

An interventional study of robotic-assisted surgery and Open Surgery in Papillary Thyroid Carcinoma and Lymphatic Metastasis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
876
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
2nd of 21
876 · median 170
Started
2024
with 9 others
No phase
14 of 40
7 open now
Primary completion
2033-12
later than 24 of 24 live
Registered
28th of 40
by date
Lead sponsor
6 of 40
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 10 that started in 2024, is one of 14 with no phase, reaches primary completion later than 24 of the 24 other live ones, and was the 28th registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

Thyroid cancer is one of the most common malignant tumors in women, ranking seventh in the United States and fourth in China. Papillary thyroid carcinoma is the most common pathological type (about 85% to 90% of thyroid cancers), and lateral cervical lymph node metastasis can reach 0.6-37.5% at diagnosis. For papillary thyroid cancer with lateral cervical lymph node metastasis, the 2015 ATA Guidelines in the United States recommend surgical resection and neck lymph node dissection as the primary treatment. Traditional cervical lymph node dissection often leaves obvious scars in the neck, which seriously affects the postoperative quality of life of patients. The previous studies have shown that endoscopy-assisted surgery with external cervical approach can achieve oncologic effects similar to traditional open surgery in the treatment of N1b papillary thyroid cancer, and can obtain better aesthetic results. However, endoscopic surgery still has some shortcomings, such as poor exposure of some surgical areas and difficult operation. Since November 2016, the investigators tried to apply modified transaxillary robotic-assisted surgery technology to the treatment of thyroid papillary carcinoma in China. The preliminary study included 30 patients, and the results showed that robot-assisted surgery via combined transaxillary-retroaural approach in the treatment of N1b papillary thyroid carcinoma achieved a good oncologic effect (5-year overall survival rate was 100.0%). As the surgical techniques improved, now the investigators can complete robotic-assisted lateral neck lymph node dissection via single-incision transaxillary approach. However, there is still a lack of high-quality evidence on the long-term oncologic outcome and quality of life of this procedure. In this study, a prospective, multi-center, randomized controlled study was conducted to compare the safety, long-term oncologic outcomes and postoperative quality of life of the robot-assisted surgery via single-incision transaxillary approach and open surgery in the treatment of N1b papillary thyroid cancer, which may provide an alternative for the patients with N1b papillary thyroid cancer.

03

Conditions studied

  • Papillary Thyroid Carcinoma
  • Lymphatic Metastasis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years old, male or female;
  • papillary thyroid carcinoma with ipsilateral lateral cervical lymph node confirmed by FNAB;
  • thyroid tumor of less than 3.0 cm in the largest diameter;
  • lack of extrathyroidal extensions as estimated by preoperative ultrasonography and CT.

Exclusion criteria

Exclusion Criteria:

  • level I or contralateral neck node .
  • enlarged lymph node of larger than 2.0 cm in the short diameter.
  • suspected perinodal infiltration of metastatic lymph nodes.
  • cervical or/and thoracic deformity.
  • life-threatening diseases of liver, kidney, heart and other organs, or abnormal coagulation function.
  • clinical evidence of distant metastases such as in the lung, bone, and so on.
  • history of previous neck surgery and/or radiation therapy.
  • intolerable to general anesthesia
  • refuse either surgical procedure
  • unwilling to cooperate with long-term follow-up evaluation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
876 participants (estimated)

Study arms

  • Experimental
    robotic-assisted surgery

    Procedure: robotic-assisted surgery

  • Other
    Open Surgery

    conventional treatment

    Procedure: Open Surgery

Interventions

  • Procedurerobotic-assisted surgery

    robotic-assisted surgery via single-incision transaxillary approach

  • ProcedureOpen Surgery

    conventional open surgery

06

What researchers measure

Primary outcomes

  1. the disease-free survival rate

    The 5-year survival rate without a functional, structural, or biological event

    Time frame: 60 months

  2. Postoperative quality of life:36-Item Short-Form Survey

    The quality of life is assessed by 36-Item Short-Form Survey (SF-36) 1 year after surgery, and the differences in physical and physiological dimensions between the two groups were compared. The higher scores mean a better outcome.

    Time frame: 12 months

Secondary outcomes

  1. Overall survival(OS)

    The time from randomization to death from any cause

    Time frame: 60 months

  2. The dynamic change trend of shoulder function

    Shoulder function is assessed using arm abduction test (0-5) to explore the dynamic change. The higher scores mean a better outcome.

    Time frame: 60 months

  3. The dynamic change trend of the postoperative quality of life

    The postoperative quality of life is assessed using 36-Item Short-Form Survey to explore the dynamic change. The higher scores mean a better outcome.

    Time frame: 60 months

  4. The dynamic change of swallowing function

    Swallowing function is assessed using Swallowing Impairment Index 6 (0-24) to explore the dynamic change. The higher scores mean a worse outcome.

    Time frame: 60 months

  5. The dynamic change trend of neck function

    Neck function is assessed using Ten-item Neck Dissection Impairment Index (0-100) to explore the dynamic change. The higher scores mean a better outcome.

    Time frame: 60 months

  6. The dynamic change trend of aesthetic satisfaction

    Aesthetic satisfaction is assessed using verbal response scale (0-10) to explore the dynamic change. The higher scores mean a better outcome.

    Time frame: 60 months

  7. The dynamic change trend of voice function

    Voice function is assessed using Voice Handicap Index 10 (0-40) to explore the dynamic change. The higher scores mean a worse outcome.

    Time frame: 60 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2033, 111 months after the start.

Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 71. This study's planned 111 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Oct 2, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Dec 31, 2033
CompletionEst.
Dec 31, 2033
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06623578
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Sep 23, 2024
Primary completion
Dec 31, 2033 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Dec 3, 2025

Study contacts

Lin
Contact
linpliang3@mail.sysu.edu.cn
0086-020-34071439

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion